Origin Therapeutics, an investment issuer focused on making equity investments in the psychedelics sector, has completed a CA$6,550,000 ($5.1 million) private placement.
The firm intends to make investments in private, early-stage psychedelics industry companies. Management told Benzinga it plans to deploy capital across a diverse group of private companies to offer investors exposure to early-stage opportunities with high growth potential.
Origin Therapeutics will work closely with its portfolio to support the growth of the companies by leveraging its management expertise and professional network.
“The psychedelics sector has such tremendous potential for growth, with the potentially positive impact on mental health being game-changing. Investors want to participate, and while there are a growing number of publicly traded companies doing great work, so much of the innovation is taking place in private companies - and we want to give investors the opportunity to participate in that growth and support it,” Alexander Somjen, CEO of Origin Therapeutics, told Benzinga.
Más contenido sobre psicodélicos en Español en El Planteo.
Photo: Dasha Yukhymyuk on Unsplash
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!